Indian Pediatrics

, Volume 56, Issue 3, pp 221–228 | Cite as

Consensus Statement of the Indian Academy of Pediatrics on Diagnosis and Management of Fragile X Syndrome in India

  • Anupam SachdevaEmail author
  • Prachi Jain
  • Vinod Gunasekaran
  • Sunita Bijarnia Mahay
  • Sharmila Mukherjee
  • Randi Hagerman
  • Suma Shankar
  • Seema Kapoor
  • Shalini N Kedia



Fragile X Syndrome (FXS) is the most common genetic cause of inherited intellectual disability and autism spectrum disorder (ASD). Early identification results in appropriate management and improvement in functioning. Risk assessment in other family members can lead to prevention of the disorder. This necessitated the formulation of IAP recommendations for the diagnosis and management of FXS in Indian children and adolescents.


The meeting on formulation of national consensus guidelines on Fragile X syndrome was organized by the Indian Academy of Pediatrics in New Delhi on 25th February, 2017. The invited experts included Pediatricians, Developmental Pediatricians, Psychiatrists, Pediatric Neurologists, Gynecologists, Geneticists, Clinical Psychologists and Remedial Educators, and representatives of Parent Organizations. Guidelines were framed after extensive discussions. A writing committee was formed that drafted the manuscript, which was circulated among members for critical appraisal, and finalized.


The committee recommended that early diagnosis of FXS is crucial for early, timely and appropriate management. The interventions including timely occupational therapy, speech therapy and behavioral modifications help to improve the developmental potential and reduce the maladaptive behavior. Pharmacotherapy may be needed to control and improve behavioral symptoms. In addition, the emergence of targeted treatments such as low dose sertraline, metformin and /or minocycline may also be helpful for behavior, and perhaps cognition. Genetic counselling is helpful to communicate the risk for future children with FXS or permutation involvement.


Genetic counselling Intellectual deficit Outcome 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hunter J, Rivero–Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of fragile X syndrome: A systematic review and meta–analysis. Am J Med Genet A. 2014;164:1648–58.CrossRefGoogle Scholar
  2. 2.
    Saldarriaga W, Tassone F, Gonzalez–Teshima LY, Forero–Forero JV, Ayala–Zapata S, Hagerman R. Fragile X syndrome. Colomb Med. 2014;45:190–8.Google Scholar
  3. 3.
    Pandey UB, Phadke S, Mittal B. Molecular screening of FRAXA and FRAXE in Indian patients with unexplained mental retardation. Genet Test. 2002;6:335–9.CrossRefGoogle Scholar
  4. 4.
    Katikala L, Guruju MR, Madireddi S, Vallamkonda O, Vallamkonda N, Persha A, et al. Distribution of CGG/GCC repeats at the FMR1 and FMR2 genes in an Indian population with mental retardation of unknown etiology. Genet Test Mol Biomarkers. 2011;15:281–4.CrossRefGoogle Scholar
  5. 5.
    Kidd SA, Lachiewicz A, Barbouth D, Blitz RK, Delahunty C, McBrien D, et al. Fragile X syndrome: A review of associated medical problems. Pediatrics. 2014;134:995–1005.CrossRefGoogle Scholar
  6. 6.
    Godler DE, Tassone F, Loesch DZ, Taylor AK, Gehling F, Hagerman RJ, et al. Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. Hum Mol Genet. 2010;19:1618–32.CrossRefGoogle Scholar
  7. 7.
    Prouty LA, Rogers RC, Stevenson RE, Dean JH, Palmer KK, Simensen RJ, et al. Fragile X syndrome: growth, development and intellectual function. Am J Med Genet. 1988;30:123–42.CrossRefGoogle Scholar
  8. 8.
    Farzin F, Perry H, Hessl D, Loesch D, Cohen J, Bacalman S, et al. Autism spectrum disorders and attention–deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr. 2006;27:S137–44.CrossRefGoogle Scholar
  9. 9.
    Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: Human genome epidemiology review. Genet Med. 2001;3:359–71.CrossRefGoogle Scholar
  10. 10.
    Yrigollen CM, Martorell L, Durbin–Johnson B, Naudo M, Genoves J, Murgia A, et al. AGG interruptions and maternal age affect FMR1 CGG repeats allele stability during transmission. J Neurodev Disord. 2014;6:24.CrossRefGoogle Scholar
  11. 11.
    Nolin SL, Sah S, Glicksman A, Sherman SL, Allen E, Berry–Kravis E, et al. Fragile X AGG analysis provides new risk predictions for 45–69 repeat alleles. Am J Med Genet A. 2013;161:771–8.CrossRefGoogle Scholar
  12. 12.
    Berry–Kravis E, Potanos K, Weinberg D, Zhou L, Goetz CG. Fragile X–associated tremor/ataxia syndrome in sisters related to X–inactivation. Ann Neurol. 2005;57:144–7.CrossRefGoogle Scholar
  13. 13.
    Hagerman R, Hagerman P. Advances in clinical and molecular understanding of FMR1 premutation and fragile X–associated tremor/ataxia syndrome. Lancet Neurol. 2013;12:786–98.CrossRefGoogle Scholar
  14. 14.
    Wheeler AC, Bailey DB, Berry–Kravis E, Greenberg J, Losh M, Mailick M, et al. Associated features in females with an FMR1 premutation. J Neurodev Disord. 2014; 6:30.CrossRefGoogle Scholar
  15. 15.
    Hagerman RJ, Hagerman P. Fragile X–associated tremor ataxia syndrome–features, mechanisms and management. Nat Rev Neurol. 2016;12:403–12.CrossRefGoogle Scholar
  16. 16.
    Filipovic–Sadic S, Sah S, Chen L, Krosting J, Sekinger E, Zhang W, et al. A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem. 2010;56:399–408.Google Scholar
  17. 17.
    Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first–tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86:749–64.CrossRefGoogle Scholar
  18. 18.
    Hess LG, Fitzpatrick SE, Nguyen DV, Chen Y, Gaul KN, Schneider A, et al. A randomized, double blind, placebocontrolled trial of low dose sertraline in young children with fragile X syndrome. J Dev Behav Pediatr. 2016;37:619–28.CrossRefGoogle Scholar
  19. 19.
    Leigh MJ, Nguyen DV, Mu Y, Winarni T, Schneider A, Chechi T, et al. A randomized double–blind placebo controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr. 2013;34:147–55.CrossRefGoogle Scholar
  20. 20.
    Dy ABC, Tassone F, Eldeeb M, Salcedo–Arellano MJ, Tartaglia N, Hagerman R. Metformin as a targeted treatment in fragile X syndrome. ClinGenet. 2018;93:216–22.Google Scholar

Copyright information

© Indian Academy of Pediatrics 2019

Authors and Affiliations

  • Anupam Sachdeva
    • 1
    • 6
    Email author
  • Prachi Jain
    • 1
  • Vinod Gunasekaran
    • 1
  • Sunita Bijarnia Mahay
    • 1
  • Sharmila Mukherjee
    • 2
  • Randi Hagerman
    • 3
  • Suma Shankar
    • 3
  • Seema Kapoor
    • 4
  • Shalini N Kedia
    • 5
  1. 1.Sir Ganga Ram HospitalNew DelhiIndia
  2. 2.Lady Hardinge Medical CollegeNew DelhiIndia
  3. 3.MIND InstituteUC DavisCaliforniaUSA
  4. 4.Maulana Azad Medical CollegeNew DelhiIndia
  5. 5.Fragile X Society; for the Indian Academy of Pediatrics Consensus in Diagnosis and Management of Fragile X Syndrome CommitteeNew DelhiIndia
  6. 6.Pediatric Hematology Oncology and Bone Marrow Transplantation unit, Institute for Child HealthSir Ganga Ram HospitalNew DelhiIndia

Personalised recommendations